Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.
Journal
Nature reviews. Urology
ISSN: 1759-4820
Titre abrégé: Nat Rev Urol
Pays: England
ID NLM: 101500082
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
accepted:
29
03
2022
pubmed:
14
5
2022
medline:
8
7
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease, but a grey area remains, encompassing high-risk localized tumours and patients with metastatic disease with a good-to-intermediate prognosis. Over the past few years, results of major practice-changing trials for the management of metastatic RCC have completely transformed the therapeutic options for this disease. Treatments targeting vascular endothelial growth factor (VEGF) have been the mainstay of therapy for metastatic RCC in the past decade, but the advent of immune checkpoint inhibitors has revolutionized the therapeutic landscape in the metastatic setting. Results from several pivotal trials have shown a substantial benefit from the combination of VEGF-directed therapy and immune checkpoint inhibition, raising new hopes for the treatment of high-risk localized RCC. The potential of these therapeutics to facilitate the surgical extirpation of the tumour in the neoadjuvant setting or to improve disease-free survival in the adjuvant setting has been investigated. The role of surgery for metastatic RCC has been redefined, with results of large trials bringing into question the paradigm of upfront cytoreductive nephrectomy, inherited from the era of cytokine therapy, when initial extirpation of the primary tumour did show clinical benefits. The potential benefits and risks of deferred surgery for residual primary tumours or metastases after partial response to checkpoint inhibitor treatment are also gaining interest, considering the long-lasting effects of these new drugs, which encourages the complete removal of residual masses.
Identifiants
pubmed: 35546184
doi: 10.1038/s41585-022-00592-3
pii: 10.1038/s41585-022-00592-3
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
391-418Informations de copyright
© 2022. Springer Nature Limited.
Références
Capitanio, U. et al. Epidemiology of renal cell carcinoma. Eur. Urol. 75, 74–84 (2019).
pubmed: 30243799
doi: 10.1016/j.eururo.2018.08.036
Bukowski, R. M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80, 1198–1220 (1997).
pubmed: 9317170
doi: 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H
Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353, 14–17 (1999).
Rosenberg, S. A. et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316, 889–897 (1987).
pubmed: 3493432
doi: 10.1056/NEJM198704093161501
Atzpodien, J., Körfer, A., Franks, C. R., Poliwoda, H. & Kirchner, H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 335, 1509–1512 (1990).
pubmed: 1972442
doi: 10.1016/0140-6736(90)93039-R
West, W. H. et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316, 898–905 (1987).
pubmed: 3493433
doi: 10.1056/NEJM198704093161502
Ljungberg, B. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur. Urol. 75, 799–810 (2019).
pubmed: 30803729
doi: 10.1016/j.eururo.2019.02.011
NCI. Cancer of the Kidney and Renal Pelvis — Cancer Stat Facts. NIH https://seer.cancer.gov/statfacts/html/kidrp.html (2022).
Patard, J.-J. et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J. Clin. Oncol. 22, 3316–3322 (2004).
pubmed: 15310775
doi: 10.1200/JCO.2004.09.104
Mickisch, G. H., Garin, A., van Poppel, H., de Prijck, L. & Sylvester, R. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966–970 (2001).
pubmed: 11583750
doi: 10.1016/S0140-6736(01)06103-7
Flanigan, R. C. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655–1659 (2001).
pubmed: 11759643
doi: 10.1056/NEJMoa003013
Flanigan, R. C. Debulking nephrectomy in metastatic renal cancer. Clin. Cancer Res. 10, 6335S–6341SS (2004).
pubmed: 15448027
doi: 10.1158/1078-0432.CCR-sup-040026
Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581–594.e12 (2018).
pubmed: 29656895
pmcid: 5938365
doi: 10.1016/j.cell.2018.03.057
Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
pubmed: 17215529
doi: 10.1056/NEJMoa065044
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
pubmed: 26406148
pmcid: 5719487
doi: 10.1056/NEJMoa1510665
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
pubmed: 29562145
pmcid: 5972549
doi: 10.1056/NEJMoa1712126
ESMO. eUpdate — renal cell carcinoma treatment recommendations. ESMO https://www.esmo.org/guidelines/genitourinary-cancers/renal-cell-carcinoma/eupdate-renal-cell-carcinoma-treatment-recommendations-3 (2020).
Méjean, A. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N. Engl. J. Med. 379, 417–427 (2018).
pubmed: 29860937
doi: 10.1056/NEJMoa1803675
Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 30, 706–720 (2019).
pubmed: 30788497
doi: 10.1093/annonc/mdz056
Baldewijns, M. M. L., van Vlodrop, I. J. H. & Schouten, L. J. Soetekouw PMMB, de Bruïne AP, van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim. Biophys. Acta 1785, 133–155 (2008).
pubmed: 18187049
Motzer, R. J., Bander, N. H. & Nanus, D. M. Renal-cell carcinoma. N. Engl. J. Med. 335, 865–875 (1996).
pubmed: 8778606
doi: 10.1056/NEJM199609193351207
Buti, S. et al. Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs 24, 535–554 (2013).
pubmed: 23552469
doi: 10.1097/CAD.0b013e3283609ec1
Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007).
pubmed: 18156031
doi: 10.1016/S0140-6736(07)61904-7
Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).
pubmed: 19487381
pmcid: 3646307
doi: 10.1200/JCO.2008.20.1293
Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).
pubmed: 17538086
doi: 10.1056/NEJMoa066838
Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).
pubmed: 18653228
doi: 10.1016/S0140-6736(08)61039-9
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 20, 1370–1385 (2019).
pubmed: 31427204
pmcid: 7497870
doi: 10.1016/S1470-2045(19)30413-9
Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289–1300 (2021).
pubmed: 33616314
doi: 10.1056/NEJMoa2035716
Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).
pubmed: 30779529
doi: 10.1056/NEJMoa1816714
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).
pubmed: 30779531
pmcid: 6716603
doi: 10.1056/NEJMoa1816047
Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829–841 (2021).
pubmed: 33657295
pmcid: 8436591
doi: 10.1056/NEJMoa2026982
Akhtar, M., Al-Bozom, I. A., Al & Hussain, T. Molecular and metabolic basis of clear cell carcinoma of the kidney. Adv. Anat. Pathol. 25, 189–196 (2018).
pubmed: 29465421
doi: 10.1097/PAP.0000000000000185
NCBI. VHL von Hippel-Lindau tumor suppressor [Homo sapiens (human)] — Genev — NCBI. NIH https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=7428 (2022).
Kaelin, W. G. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13, 680s–684ss (2007).
pubmed: 17255293
doi: 10.1158/1078-0432.CCR-06-1865
Los, M., Roodhart, J. M. L. & Voest, E. E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12, 443–450 (2007).
pubmed: 17470687
doi: 10.1634/theoncologist.12-4-443
Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117–1134 (2010).
pubmed: 20602996
pmcid: 2914105
doi: 10.1016/j.cell.2010.06.011
Zwick, E., Bange, J. & Ullrich, A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr. Relat. Cancer 8, 161–173 (2001).
pubmed: 11566607
doi: 10.1677/erc.0.0080161
Robinson, C. J. & Stringer, S. E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114, 853–865 (2001).
pubmed: 11181169
doi: 10.1242/jcs.114.5.853
Porter, A. C. & Vaillancourt, R. R. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17, 1343–1352 (1998).
pubmed: 9779982
doi: 10.1038/sj.onc.1202171
Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
pubmed: 17215530
doi: 10.1056/NEJMoa060655
Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061–1068 (2010).
pubmed: 20100962
doi: 10.1200/JCO.2009.23.9764
Rini, B. I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378, 1931–1939 (2011).
pubmed: 22056247
doi: 10.1016/S0140-6736(11)61613-9
Motzer, R. J. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1482 (2015).
pubmed: 26482279
doi: 10.1016/S1470-2045(15)00290-9
Rini, B. I. et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 21, 95–104 (2020).
pubmed: 31810797
doi: 10.1016/S1470-2045(19)30735-1
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03680521 (2021).
Cohen, R. B. & Oudard, S. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest. N. Drugs 30, 2066–2079 (2012).
doi: 10.1007/s10637-012-9796-8
Kollmannsberger, C. Sunitinib side effects as surrogate biomarkers of efficacy. Can. Urol. Assoc. J. 10, S245–S247 (2016).
pubmed: 28096937
pmcid: 5215302
doi: 10.5489/cuaj.4315
Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes. Dev. 18, 1926–1945 (2004).
pubmed: 15314020
doi: 10.1101/gad.1212704
Yin, Y. et al. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. Cell Res. 26, 46–65 (2016).
pubmed: 26584640
doi: 10.1038/cr.2015.133
Faes, S., Demartines, N. & Dormond, O. Mechanistic target of rapamycin inhibitors in renal cell carcinoma: potential, limitations, and perspectives. Front. Cell Dev. Biol. 9, 636037 (2021).
pubmed: 33791295
pmcid: 8005589
doi: 10.3389/fcell.2021.636037
Loewith, R. et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457–468 (2002).
pubmed: 12408816
doi: 10.1016/S1097-2765(02)00636-6
Albiges, L. et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann. Oncol. 23, 1943–1953 (2012).
pubmed: 22689175
doi: 10.1093/annonc/mds115
Rodriguez-Pascual, J., Cheng, E., Maroto, P. & Duran, I. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 21, 478–486 (2010).
pubmed: 20401967
doi: 10.1097/CAD.0b013e32833760bf
Penttilä, P. et al. Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. Eur. J. Cancer 81, 9–16 (2017).
pubmed: 28586749
doi: 10.1016/j.ejca.2017.05.004
Braun, D. A. et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39, 632–648.e8 (2021).
pubmed: 33711273
pmcid: 8138872
doi: 10.1016/j.ccell.2021.02.013
Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
pubmed: 22437870
pmcid: 4856023
doi: 10.1038/nrc3239
Zhang, Y. & Zheng, J. Functions of immune checkpoint molecules beyond immune evasion. Adv. Exp. Med. Biol. 1248, 201–226 (2020).
pubmed: 32185712
doi: 10.1007/978-981-15-3266-5_9
Iwai, Y., Hamanishi, J., Chamoto, K. & Honjo, T. Cancer immunotherapies targeting the PD-1 signaling pathway. J. Biomed. Sci. 24, 26 (2017).
pubmed: 28376884
pmcid: 5381059
doi: 10.1186/s12929-017-0329-9
Walunas, T. L. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1, 405–413 (1994).
pubmed: 7882171
doi: 10.1016/1074-7613(94)90071-X
Qureshi, O. S. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332, 600–603 (2011).
pubmed: 21474713
pmcid: 3198051
doi: 10.1126/science.1202947
Carlo, M. I., Voss, M. H. & Motzer, R. J. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat. Rev. Urol. 13, 420–431 (2016).
pubmed: 27324121
pmcid: 5532875
doi: 10.1038/nrurol.2016.103
Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293–12297 (2002).
pubmed: 12218188
pmcid: 129438
doi: 10.1073/pnas.192461099
Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767–1778 (2016).
pubmed: 27806234
pmcid: 5575761
doi: 10.1056/NEJMra1514296
Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765–772 (1996).
pubmed: 8671665
doi: 10.1093/intimm/8.5.765
Okazaki, T. & Honjo, T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19, 813–824 (2007).
pubmed: 17606980
doi: 10.1093/intimm/dxm057
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
pubmed: 26027431
pmcid: 5698905
doi: 10.1056/NEJMoa1504030
Comin-Anduix, B., Escuin-Ordinas, H. & Ibarrondo, F. J. Tremelimumab: research and clinical development. Onco Targets Ther. 9, 1767–1776 (2016).
pubmed: 27042127
pmcid: 4809326
Massard, C. et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34, 3119–3125 (2016).
pubmed: 27269937
pmcid: 5569690
doi: 10.1200/JCO.2016.67.9761
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03288532 (2020).
Drugs.com. Pembrolizumab monograph for professionals. Drugs.com https://www.drugs.com/monograph/pembrolizumab.html (2021).
Choueiri, T. K. et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med. 385, 683–694 (2021).
pubmed: 34407342
doi: 10.1056/NEJMoa2106391
AdisInsight. Toripalimab — Shanghai Junshi Biosciences — AdisInsight. AdisInsight https://adisinsight.springer.com/drugs/800046697 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04385654 (2020).
Rini, B. I. et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393, 2404–2415 (2019).
pubmed: 31079938
doi: 10.1016/S0140-6736(19)30723-8
Drugs.com. Avelumab monograph for professionals. Drugs.com https://www.drugs.com/monograph/avelumab.html (2022).
Weber, J. S., Yang, J. C., Atkins, M. B. & Disis, M. L. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33, 2092–2099 (2015).
pubmed: 25918278
pmcid: 4881375
doi: 10.1200/JCO.2014.60.0379
Zhou, X. et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 18, 87 (2020).
pubmed: 32306958
pmcid: 7169020
doi: 10.1186/s12916-020-01549-2
Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974–1982 (2015).
pubmed: 25605845
pmcid: 4980573
doi: 10.1200/JCO.2014.59.4358
EAU. EAU Guidelines: renal cell carcinoma. Uroweb https://uroweb.org/guideline/renal-cell-carcinoma/#note_472 (2022).
Heng, D. Y. C. et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 14, 141–148 (2013).
pubmed: 23312463
pmcid: 4144042
doi: 10.1016/S1470-2045(12)70559-4
Heng, D. Y. C. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794–5799 (2009).
pubmed: 19826129
doi: 10.1200/JCO.2008.21.4809
Ljungberg, B. et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 58, 398–406 (2010).
pubmed: 20633979
doi: 10.1016/j.eururo.2010.06.032
Albiges, L. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 5, e001079 (2020).
pubmed: 33246931
pmcid: 7703447
doi: 10.1136/esmoopen-2020-001079
Tannir, N. M. et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin. Cancer Res. 27, 78–86 (2021).
pubmed: 32873572
doi: 10.1158/1078-0432.CCR-20-2063
Shuch, B. et al. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int. 109, 1600–1606 (2012).
pubmed: 22221668
pmcid: 4676716
doi: 10.1111/j.1464-410X.2011.10785.x
Cella, D. et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 20, 297–310 (2019).
pubmed: 30658932
pmcid: 6701190
doi: 10.1016/S1470-2045(18)30778-2
Powles, T. et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 21, 1563–1573 (2020).
pubmed: 33284113
doi: 10.1016/S1470-2045(20)30436-8
Atkins, M. B. et al. Patient-reported outcomes from the phase III randomized IMmotion151 trial: atezolizumab + bevacizumab versus sunitinib in treatment-naïve metastatic renal cell carcinoma. Clin. Cancer Res. 26, 2506–2514 (2020).
pubmed: 32127394
pmcid: 8407399
doi: 10.1158/1078-0432.CCR-19-2838
Klaassen, Z. ASCO 2021: health-related quality-of-life analysis from the phase 3 CLEAR trial of lenvatinib + pembrolizumab or everolimus versus sunitinib for patients with advanced RCC. Uro Today https://www.urotoday.com/conference-highlights/asco-2021/asco-2021-kidney-cancer/130132-asco-2021-health-related-quality-of-life-analysis-from-the-phase-3-clear-trial-of-lenvatinib-pembrolizumab-or-everolimus-versus-sunitinib-for-patients-with-advanced-rcc.amp.html (2021).
Bedke, J. et al. The 2021 updated European Association of Urology Guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care. Eur. Urol. 80, 393–397 (2021).
pubmed: 34074559
doi: 10.1016/j.eururo.2021.04.042
Law, T. M. et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824–832 (1995).
pubmed: 8625186
doi: 10.1002/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N
O’Neill, L. A. J., Kishton, R. J. & Rathmell, J. A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 16, 553–565 (2016).
pubmed: 27396447
pmcid: 5001910
doi: 10.1038/nri.2016.70
Bhindi, B. et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur. Urol. 75, 111–128 (2019).
pubmed: 30467042
doi: 10.1016/j.eururo.2018.09.016
Posadas, E. M. & Figlin, R. A. Kidney cancer: progress and controversies in neoadjuvant therapy. Nat. Rev. Urol. 11, 254–255 (2014).
pubmed: 24752207
doi: 10.1038/nrurol.2014.89
Rini, B. I. et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J. Urol. 194, 297–303 (2015).
pubmed: 25813447
doi: 10.1016/j.juro.2015.03.096
Cai, W. et al. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study. Cancer Commun. 39, 56 (2019).
doi: 10.1186/s40880-019-0405-5
Hatiboglu, G. et al. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. Langenbecks Arch. Surg. 402, 637–644 (2017).
pubmed: 28012035
doi: 10.1007/s00423-016-1543-8
Lebacle, C. et al. Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study. BJU Int. 123, 804–810 (2019).
pubmed: 30288884
doi: 10.1111/bju.14581
Silberstein, J. L. et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 106, 1270–1276 (2010).
pubmed: 20394613
doi: 10.1111/j.1464-410X.2010.09357.x
Roy, A. M., Briggler, A., Tippit, D., Dawson, K. & Verma, R. Neoadjuvant cabozantinib in renal-cell carcinoma: a brief review. Clin. Genitourin. Cancer 18, e688–e691 (2020).
pubmed: 32660880
doi: 10.1016/j.clgc.2020.04.003
Cowey, C. L. et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol. 28, 1502–1507 (2010).
pubmed: 20159822
pmcid: 4525128
doi: 10.1200/JCO.2009.24.7759
Field, C. A. et al. Neoadjuvant sunitinib decreases inferior vena caval thrombus size and is associated with improved oncologic outcomes: a multicenter comparative analysis. Clin. Genitourin. Cancer 17, e505–e512 (2019).
pubmed: 30808547
doi: 10.1016/j.clgc.2019.01.013
Bex, A. et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J. Urol. 27, 533–539 (2009).
pubmed: 19145434
doi: 10.1007/s00345-008-0368-7
Bigot, P. et al. Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World J. Urol. 32, 109–114 (2014).
pubmed: 23624719
doi: 10.1007/s00345-013-1088-1
Karam, J. A. et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur. Urol. 66, 874–880 (2014).
pubmed: 24560330
pmcid: 4396847
doi: 10.1016/j.eururo.2014.01.035
Hellenthal, N. J. et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J. Urol. 184, 859–864 (2010).
pubmed: 20643461
pmcid: 3105599
doi: 10.1016/j.juro.2010.05.041
Thomas, A. A. et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181, 518–523 (2009). discussion 523.
pubmed: 19100579
doi: 10.1016/j.juro.2008.10.001
Zhang, Y. et al. Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma. PLoS One 10, e0115896 (2015).
pubmed: 25647522
pmcid: 4315594
doi: 10.1371/journal.pone.0115896
Rini, B. I. et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J. Urol. 187, 1548–1554 (2012).
pubmed: 22425095
doi: 10.1016/j.juro.2011.12.075
Cost, N. G. et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur. Urol. 59, 912–918 (2011).
pubmed: 21367518
doi: 10.1016/j.eururo.2011.02.032
van der Veldt, A. A. M. et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin. Cancer Res. 14, 2431–2436 (2008).
pubmed: 18413834
doi: 10.1158/1078-0432.CCR-07-4089
Hutson, T. E., Thoreson, G. R., Figlin, R. A. & Rini, B. I. The evolution of systemic therapy in metastatic renal cell carcinoma. Am. Soc. Clin. Oncol. Educ. Book. 35, 113–117 (2016).
pubmed: 27249692
doi: 10.1200/EDBK_158892
Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1814–1823 (2015).
pubmed: 26406150
pmcid: 5024539
doi: 10.1056/NEJMoa1510016
Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205–216 (2000).
pubmed: 10655437
doi: 10.1093/jnci/92.3.205
AUA. Renal Cancer: renal mass & localized renal cancer guideline. AUA https://www.auanet.org/guidelines/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline (2017).
Russo, P. Oncological and renal medical importance of kidney-sparing surgery. Nat. Rev. Urol. 10, 292–299 (2013).
pubmed: 23459033
doi: 10.1038/nrurol.2013.34
Van Poppel, H. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur. Urol. 59, 543–552 (2011).
pubmed: 21186077
doi: 10.1016/j.eururo.2010.12.013
Lane, B. R. et al. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol. Oncol. 33, 112.e15–21 (2015).
doi: 10.1016/j.urolonc.2014.11.009
Kutikov, A. & Uzzo, R. G. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J. Urol. 182, 844–853 (2009).
pubmed: 19616235
doi: 10.1016/j.juro.2009.05.035
Pfizer. SUTENT prescribing information. Pfizer http://labeling.pfizer.com/showlabeling.aspx?id=607 (2006).
Minami, H. et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 99, 1492–1498 (2008).
pubmed: 18477034
doi: 10.1111/j.1349-7006.2008.00837.x
Mootha, R. K., Butler, R., Laucirica, R., Scardino, P. T. & Lerner, S. P. Renal cell carcinoma with an infrarenal vena caval tumor thrombus. Urology 54, 561 (1999).
pubmed: 10754141
doi: 10.1016/S0090-4295(99)00136-3
Neves, R. J. & Zincke, H. Surgical treatment of renal cancer with vena cava extension. Br. J. Urol. 59, 390–395 (1987).
pubmed: 3594097
doi: 10.1111/j.1464-410X.1987.tb04832.x
Karnes, R. J. & Blute, M. L. Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus. Nat. Clin. Pract. Urol. 5, 329–339 (2008).
pubmed: 18477994
doi: 10.1038/ncpuro1122
Labbate, C. et al. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J. Immunother. Cancer 7, 66 (2019).
pubmed: 30857555
pmcid: 6413449
doi: 10.1186/s40425-019-0546-8
Singla, N. et al. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. Urol. Oncol. 37, 924–931 (2019).
pubmed: 31522865
doi: 10.1016/j.urolonc.2019.08.012
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02212730 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02575222 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02595918 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02762006 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03055013 (2022).
Dall’Olio, F. G. et al. Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy 13, 257–270 (2021).
pubmed: 33225800
doi: 10.2217/imt-2020-0179
Bex, A. et al. Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx). J. Clin. Oncol. 40, 289–289 (2022).
doi: 10.1200/JCO.2022.40.6_suppl.289
Pizzocaro, G. et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol. 19, 425–431 (2001).
pubmed: 11208835
doi: 10.1200/JCO.2001.19.2.425
Messing, E. M. et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J. Clin. Oncol. 21, 1214–1222 (2003).
pubmed: 12663707
doi: 10.1200/JCO.2003.02.005
Clark, J. I. et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J. Clin. Oncol. 21, 3133–3140 (2003).
pubmed: 12810695
doi: 10.1200/JCO.2003.02.014
Passalacqua, R. et al. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). J. Immunother. 37, 440–447 (2014).
pubmed: 25304727
doi: 10.1097/CJI.0000000000000055
Jocham, D. et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363, 594–599 (2004).
pubmed: 14987883
doi: 10.1016/S0140-6736(04)15590-6
Janowitz, T., Welsh, S. J., Zaki, K., Mulders, P. & Eisen, T. Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin. Oncol. 40, 482–491 (2013).
pubmed: 23972712
pmcid: 3765962
doi: 10.1053/j.seminoncol.2013.05.004
Janzen, N. K., Kim, H. L., Figlin, R. A. & Belldegrun, A. S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North. Am. 30, 843–852 (2003).
pubmed: 14680319
doi: 10.1016/S0094-0143(03)00056-9
Porta, C. et al. The adjuvant treatment of kidney cancer: a multidisciplinary outlook. Nat. Rev. Nephrol. 15, 423–433 (2019).
pubmed: 30914797
doi: 10.1038/s41581-019-0131-x
Haas N. B., Uzzo R. G. Perioperative therapy in renal cell carcinoma: what do we know, what have we learned, what’s next? J. Clin. Oncol. 36, 3608–3614 (2018).
doi: 10.1200/JCO.2018.78.9131
Figlin, R. A., Leibovich, B. C., Stewart, G. D. & Negrier, S. Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success? Ann. Oncol. 29, 324–331 (2018).
pubmed: 29186296
doi: 10.1093/annonc/mdx743
Frank, I. et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168, 2395–2400 (2002).
pubmed: 12441925
doi: 10.1016/S0022-5347(05)64153-5
Leibovich, B. C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97, 1663–1671 (2003).
pubmed: 12655523
doi: 10.1002/cncr.11234
Zisman, A. et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19, 1649–1657 (2001).
pubmed: 11250993
doi: 10.1200/JCO.2001.19.6.1649
Cortellini, A. et al. Predictive ability for disease-free survival of the GRade, Age, Nodes, and Tumor (GRANT) score in patients with resected renal cell carcinoma. Curr. Urol. 14, 98–104 (2020).
pubmed: 32774235
pmcid: 7390980
doi: 10.1159/000499252
Brooks, S. A. et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur. Urol. 66, 77–84 (2014).
pubmed: 24613583
pmcid: 4058355
doi: 10.1016/j.eururo.2014.02.035
Rini, B. et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. 16, 676–685 (2015).
pubmed: 25979595
doi: 10.1016/S1470-2045(15)70167-1
Ingels A., et al. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study. World J. Urol. 35, 81–87 (2016)
pubmed: 27207480
doi: 10.1007/s00345-016-1854-y
Haas, N. B. et al. Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial. JAMA Oncol. 3, 1249–1252 (2017).
pubmed: 28278333
pmcid: 5591751
doi: 10.1001/jamaoncol.2017.0076
Motzer, R. J. et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J. Clin. Oncol. 35, 3916–3923 (2017).
pubmed: 28902533
pmcid: 6018511
doi: 10.1200/JCO.2017.73.5324
Gross-Goupil M., et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann. Oncol. 29, 2371–2378 (2018).
pubmed: 30346481
pmcid: 6311952
doi: 10.1093/annonc/mdy454
Ravaud, A. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N. Engl. J. Med. 375, 2246–2254 (2016).
pubmed: 27718781
doi: 10.1056/NEJMoa1611406
Motzer, R. J. et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur. Urol. 73, 62–68 (2018).
pubmed: 28967554
doi: 10.1016/j.eururo.2017.09.008
Larroquette, M. et al. Adjuvant therapy in renal cell carcinoma: current knowledges and future perspectives. Cancer Treat. Rev. 97, 102207 (2021).
pubmed: 33906023
doi: 10.1016/j.ctrv.2021.102207
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/record/NCT01120249 (2021).
Sun, M. et al. Adjuvant vascular endothelial growth factor-targeted therapy in renal cell carcinoma: a systematic review and pooled analysis. Eur. Urol. 74, 611–620 (2018).
pubmed: 29784193
pmcid: 7515772
doi: 10.1016/j.eururo.2018.05.002
Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25, iii49–iii56 (2014).
pubmed: 25210086
doi: 10.1093/annonc/mdu259
Rini, B. I. et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J. Immunother. Cancer 7, 354 (2019).
pubmed: 31856918
pmcid: 6924043
doi: 10.1186/s40425-019-0813-8
Palumbo, C. et al. A plea for optimizing selection in current adjuvant immunotherapy trials for high-risk nonmetastatic renal cell carcinoma according to expected cancer-specific mortality. Clin. Genitourin. Cancer 18, 314–321.e1 (2020).
pubmed: 32482565
doi: 10.1016/j.clgc.2019.11.010
Eggermont, A. M. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).
pubmed: 25840693
doi: 10.1016/S1470-2045(15)70122-1
Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824–1835 (2017).
pubmed: 28891423
doi: 10.1056/NEJMoa1709030
Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102–2114 (2021).
pubmed: 34077643
pmcid: 8215888
doi: 10.1056/NEJMoa2034442
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03024996 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03138512 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03142334 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03055013 (2022).
Harshman, L. C. et al. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: a trial-level meta-analysis. Cancer 124, 925–933 (2018).
pubmed: 29266178
doi: 10.1002/cncr.31154
FDA. Renal cell carcinoma: developing drugs and biologics for adjuvant treatment. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/renal-cell-carcinoma-developing-drugs-and-biologics-adjuvant-treatment (2020).
Bedke, J. et al. 2021 Updated European Association of Urology guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma. Eur. Urol. 82, 134–137 (2021).
Martinez Chanza, N., Tripathi, A. & Harshman, L. C. Adjuvant therapy options in renal cell carcinoma: where do we stand? Curr. Treat. Options Oncol. 20, 44 (2019).
pubmed: 31054006
doi: 10.1007/s11864-019-0639-0
Mazzaschi, G., Quaini, F., Bersanelli, M. & Buti, S. Cytoreductive nephrectomy in the era of targeted- and immuno-therapy for metastatic renal cell carcinoma: an elusive issue? A systematic review of the literature. Crit. Rev. Oncol. Hematol. 160, 103293 (2021).
pubmed: 33667661
doi: 10.1016/j.critrevonc.2021.103293
Culp, S. H. et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116, 3378–3388 (2010).
pubmed: 20564061
doi: 10.1002/cncr.25046
Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. Lancet 373, 1119–1132 (2009).
pubmed: 19269025
doi: 10.1016/S0140-6736(09)60229-4
Bex, A. et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 5, 164–170 (2019).
pubmed: 30543350
doi: 10.1001/jamaoncol.2018.5543
Roussel, E. et al. Rates and predictors of perioperative complications in cytoreductive nephrectomy: analysis of the registry for metastatic renal cell carcinoma. Eur. Urol. Oncol. 3, 523–529 (2020).
pubmed: 32414697
doi: 10.1016/j.euo.2020.04.006
Choueiri, T. K. et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J. Urol. 185, 60–66 (2011).
pubmed: 21074201
doi: 10.1016/j.juro.2010.09.012
Motzer, R. J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530–2540 (1999).
pubmed: 10561319
doi: 10.1200/JCO.1999.17.8.2530
De Bruijn, R. E. et al. Surgical safety of cytoreductive nephrectomy following sunitinib: results from the multicentre, randomised controlled trial of immediate versus deferred nephrectomy (SURTIME). Eur. Urol. 76, 437–440 (2019).
pubmed: 31227307
doi: 10.1016/j.eururo.2019.06.006
Méjean, A. et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur. Urol. 80, 417–424 (2021).
pubmed: 34187771
doi: 10.1016/j.eururo.2021.06.009
Rini, B. I. et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 17, 1317–1324 (2016).
pubmed: 27498080
pmcid: 9199453
doi: 10.1016/S1470-2045(16)30196-6
Roussel E., et al. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. Scand. J. Urol. 54, 493-499 (2020).
Mason, R. J. et al. Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Can. Urol. Assoc. J. 13, 166–174 (2019).
pubmed: 31199235
Bex, A. et al. Updated European Association of Urology guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma. Eur. Urol. 74, 805–809 (2018).
pubmed: 30177291
doi: 10.1016/j.eururo.2018.08.008
Motzer, R. J. et al. NCCN guidelines insights: kidney cancer, version 1.2021. J. Natl Compr. Cancer Netw. 18, 1160–1170 (2020).
doi: 10.6004/jnccn.2020.0043
Motzer, R. J. & Russo, P. Cytoreductive nephrectomy — patient selection is key. N. Engl. J. Med. 379, 481–482 (2018).
pubmed: 29860908
doi: 10.1056/NEJMe1806331
Larcher, A. et al. Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for renal cell carcinoma guidelines. Eur. Urol. 78, 321–326 (2020).
pubmed: 32507335
doi: 10.1016/j.eururo.2020.05.014
Larcher, A. et al. Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates? Eur. Urol. Oncol. 2, 365–378 (2019).
pubmed: 31109902
doi: 10.1016/j.euo.2019.04.007
Mejean, A. et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): update on Carmena trial with focus on intermediate IMDC-risk population. J. Clin. Oncol. 37, 4508–4508 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.4508
Bhindi, B. et al. Deferred cytoreductive nephrectomy in patients with newly diagnosed metastatic renal cell carcinoma. Eur. Urol. 78, 615–623 (2020).
pubmed: 32362493
doi: 10.1016/j.eururo.2020.04.038
Méjean, A. Primum non nocere: when nephrectomy becomes a selective approach in metastatic renal cell carcinoma. Eur. Urol. Oncol. 3, 174–175 (2020).
pubmed: 32201134
doi: 10.1016/j.euo.2020.02.008
Albiges, L. et al. Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur. Urol. 76, 151–156 (2019).
pubmed: 31151678
doi: 10.1016/j.eururo.2019.05.022
Liu, J. et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6, 1382–1399 (2016).
pubmed: 27663893
doi: 10.1158/2159-8290.CD-16-0577
Kinsey, E. N. & George, D. Can I get a multidisciplinary consult, please? Systemic immunotherapy and the timing of cytoreductive nephrectomy. Eur. Urol. Focus 6, 9–10 (2020).
pubmed: 31147262
doi: 10.1016/j.euf.2019.05.013
Bakouny, Z. et al. Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): a propensity score-based analysis. J. Clin. Oncol. 38, 608 (2020).
doi: 10.1200/JCO.2020.38.6_suppl.608
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03977571 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04510597 (2021).
Jonasch, E. et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 4076–4081 (2009).
pubmed: 19636008
pmcid: 4371138
doi: 10.1200/JCO.2008.21.3660
Powles, T. et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur. Urol. 60, 448–454 (2011).
pubmed: 21612860
doi: 10.1016/j.eururo.2011.05.028
Bex, A. et al. A phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). Future Oncol. 15, 2203–2209 (2019).
pubmed: 31023100
doi: 10.2217/fon-2019-0111
Reimers, M. A. et al. Elective cytoreductive nephrectomy after checkpoint inhibitor immunotherapy in patients with initially unresectable metastatic clear cell renal cell carcinoma. Clin. Genitourin. Cancer 18, 361–366 (2020).
pubmed: 32417157
pmcid: 7541406
doi: 10.1016/j.clgc.2020.04.002
Pignot, G. et al. Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge? Eur. Urol. 77, 761–763 (2020).
pubmed: 31911011
doi: 10.1016/j.eururo.2019.12.018
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02210117 (2020).
Epaillard, N. et al. BIONIKK: a phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bull. Cancer 107, eS22–eS27 (2020).
pubmed: 32620212
doi: 10.1016/S0007-4551(20)30283-6
Beuselinck, B. et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin. Cancer Res. 21, 1329–1339 (2015).
pubmed: 25583177
doi: 10.1158/1078-0432.CCR-14-1128
Roussel, E. et al. Molecular subtypes and gene expression signatures as prognostic features in fully resected clear cell renal cell carcinoma: a tailored approach to adjuvant trials. Clin. Genitourin. Cancer 19, e382–e394 (2021).
McDermott, D. F. et al. Publisher correction: clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 1941 (2018).
pubmed: 30291359
doi: 10.1038/s41591-018-0235-z
Najjar, Y. G. et al. Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1β, IL8, CXCL5, and Mip-1α. Clin. Cancer Res. 23, 2346–2355 (2017).
pubmed: 27799249
doi: 10.1158/1078-0432.CCR-15-1823
Osada, T. et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57, 1115–1124 (2008).
pubmed: 18193223
pmcid: 4110970
doi: 10.1007/s00262-007-0441-x
Hannan, R. et al. Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer. J. Clin. Oncol. 39, 311–311 (2021).
doi: 10.1200/JCO.2021.39.6_suppl.311
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04090710 (2022).
Jadvar, H., Chen, X., Cai, W. & Mahmood, U. Radiotheranostics in cancer diagnosis and management. Radiology. 286, 388–400 (2018).
pubmed: 29356634
doi: 10.1148/radiol.2017170346
Courcier, J. et al. Carbonic anhydrase IX in renal cell carcinoma, implications for disease management. Int. J. Mol. Sci. 21, E7146 (2020).
pubmed: 32998233
doi: 10.3390/ijms21197146
Muselaers, C. H. J. et al. Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur. Urol. 69, 767–770 (2016).
pubmed: 26706103
doi: 10.1016/j.eururo.2015.11.033
Filetti, S. et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 30, 1856–1883 (2019).
pubmed: 31549998
doi: 10.1093/annonc/mdz400
Hofman, M. S. et al. [
pubmed: 33581798
doi: 10.1016/S0140-6736(21)00237-3
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04118855 (2019).
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P. & Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289–296 (2002).
pubmed: 11773181
doi: 10.1200/JCO.2002.20.1.289
de Velasco, G. et al. A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial. Oncotarget. 11, 4457–4462 (2020).
pubmed: 33315988
pmcid: 7720770
doi: 10.18632/oncotarget.27807
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04393350 (2022).